Form 8-K - Current report:
SEC Accession No. 0001731122-25-000312
Filing Date
2025-02-28
Accepted
2025-02-28 16:05:41
Documents
16
Period of Report
2025-02-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K e6390_8-k.htm   iXBRL 8-K 36609
2 EXHIBIT 2.1 e6390_ex2-1.htm EX-2.1 575875
3 EXHIBIT 99.1 e6390_ex99-1.htm EX-99.1 11807
4 GRAPHIC image_001.jpg GRAPHIC 6852
  Complete submission text file 0001731122-25-000312.txt   939667

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE renb-20250226.xsd EX-101.SCH 3030
6 XBRL LABEL FILE renb-20250226_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE renb-20250226_pre.xml EX-101.PRE 24175
18 EXTRACTED XBRL INSTANCE DOCUMENT e6390_8-k_htm.xml XML 3683
Mailing Address CENTURY CITY MEDICAL PLAZA 2080 CENTURY CITY EAST SUITE 906 LOS ANGELES CA 90067
Business Address CENTURY CITY MEDICAL PLAZA 2080 CENTURY CITY EAST SUITE 906 LOS ANGELES CA 90067 45 39179840
RENOVARO INC. (Filer) CIK: 0001527728 (see all company filings)

EIN.: 452259340 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-38758 | Film No.: 25690017
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)